TIVC supply chain intelligence for Valion Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Valion Bio, Inc. (TIVC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MERCHANTS-ICE-II-LLC | MERCHANTS-ICE-II-LLC | 90% | VBI shall pay Merchants Ice II a monthly base rent of $55,029.73 for the first twelve months, or a total of $660,356.78, with annual increases of approximately 3.0% |
| SCORPIUS | SCORPIUS | 90% | Prior to the acquisition, Scorpius served as the primary U.S. manufacturer for the Company's late-stage TLR5 agonist, Entolimod, for the treatment of acute radiation syndrome. |
| TPB-MERCHANTS-ICE-LLC | TPB-MERCHANTS-ICE-LLC | 90% | VBI shall pay TPB a monthly base rent of approximately $22,605 for the first twelve months, or a total of $271,260, with annual dollar increases in later years of the lease term |
| VELOCITY | VELOCITY | 85% | This acquisition included the integration of approximately 40 specialized technical personnel, providing the Company with direct oversight of the Entolimod manufacturing lifecycle. |
| TEXAS-RESEARCH-AND-TECHNOLOGY-FOUNDATION | TEXAS-RESEARCH-AND-TECHNOLOGY-FOUNDATION | 80% | VBI entered into a Sublease (the "Office Sublease") with Texas Research and Technology Foundation |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TEXAS-RESEARCH-AND-TECHNOLOGY-FOUNDATION | TEXAS-RESEARCH-AND-TECHNOLOGY-FOUNDATION | 85% | VBI entered into a Sublease (the "Office Sublease") with Texas Research and Technology Foundation |
| TPB-MERCHANTS-ICE-LLC | TPB-MERCHANTS-ICE-LLC | 85% | perience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Cash and Cash Equivalents The Company considers all highly liquid investments with origina… |
| STAB | STAB | 72% | for the treatment of ARS. Furthermore, the Company holds Investigational New Drug ("IND") applications for Entolimod in both ARS and advanced oncology, with plans to advance Entolimod and its optimiz… |
| STAB | STAB | 72% | Reciprocal relationship from STAB graph: Reciprocal relationship from TIVC graph: for the treatment of ARS. Furthermore, the Company holds Investigational New Drug ("IND") applications for Entolimod … |
| TCRT | Alaunos Therapeutics, Inc. | 72% | Reciprocal relationship from TCRT graph: Reciprocal relationship from TIVC graph: Reciprocal relationship from TCRT graph: Reciprocal relationship from TIVC graph: for the treatment of ARS. Furthermo… |
| TCRT | Alaunos Therapeutics, Inc. | 72% | for the treatment of ARS. Furthermore, the Company holds Investigational New Drug ("IND") applications for Entolimod in both ARS and advanced oncology, with plans to advance Entolimod and its optimiz… |
| VBIO | VBIO | 72% | Reciprocal relationship from VBIO graph: Reciprocal relationship from TIVC graph: alion to support the manufacturing of Entolimod, the Company's lead product candidate. The Company manages its busine… |
| VBIO | VBIO | 72% | alion to support the manufacturing of Entolimod, the Company's lead product candidate. The Company manages its business activities as two operating segments, the biopharma business and the CDMO busin… |
| CELL-MEDICA-INC | CELL-MEDICA-INC | 62% | for the treatment of ARS. Furthermore, the Company holds Investigational New Drug ("IND") applications for Entolimod in both ARS and advanced oncology, with plans to advance Entolimod and its optimiz… |
| KUUR-THERAPEUTICS-INC | KUUR-THERAPEUTICS-INC | 62% | for the treatment of ARS. Furthermore, the Company holds Investigational New Drug ("IND") applications for Entolimod in both ARS and advanced oncology, with plans to advance Entolimod and its optimiz… |
| SCORPIUS-HOLDINGS | SCORPIUS-HOLDINGS | 62% | for the treatment of ARS. Furthermore, the Company holds Investigational New Drug ("IND") applications for Entolimod in both ARS and advanced oncology, with plans to advance Entolimod and its optimiz… |
| TIVIC-HEALTH-SYSTEMS-INC | TIVIC-HEALTH-SYSTEMS-INC | 62% | alion to support the manufacturing of Entolimod, the Company's lead product candidate. The Company manages its business activities as two operating segments, the biopharma business and the CDMO busin… |
| TUMIM-STONE-CAPITAL-LLC | TUMIM-STONE-CAPITAL-LLC | 62% | essional fees. Other (Expense) Income, net Other (expense) income, net, includes the change in fair value of derivative associated with the senior secured convertible note payable issued in December … |
| VELOCITY-BIOWORKS-INC | VELOCITY-BIOWORKS-INC | 62% | economy and our business may be difficult to assess or predict, these world events have resulted in, and may continue to result in, significant disruption of global financial markets, and may reduce … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TIVC-DEBT-12992 | Warrants outstanding: 61287 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| TIVC-DEBT-12993 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| TIVC-DEBT | Debt stack $6.5M | 90% | Market cache reports total debt of $6.5M. |